Dear Stakeholders,
With our bold breakthroughs in pharmaceuticals, in which we have been the industry leader since 2002, our responsibility towards our country and our passion for our work, we take bold steps towards achieving great goals, setting a new benchmark every step of the way.
At Abdi İbrahim, we embrace a future-facing mindset through our visionary perspective and innovative management approach with a view to further improving our competencies that are prerequisites for our sustainable success and strive to become a key global player with long-term planning and strategies.
Driven by our 2025 vision that will shape the next five years for Abdi İbrahim, we aim to maintain our leadership by outperforming the Turkish market in growth and double our footprint in the international markets with a powerful and ambitious growth performance.
The acquisition of OM Pharma, one of the leading biopharmaceutical companies in Switzerland, with a Swiss joint venture group marks a pivotal step we have taken towards our goals of achieving global growth, becoming an international player and further bolstering our foothold in the field of biotechnology. We are extremely pleased to showcase our strength with this bold new step that boasts a global footprint.
We have many exciting strategic milestones to reach down our pipeline, such as focusing on innovation, promoting digital transformation, making Türkiye one of the major production hubs in Europe, furthering our new product development efforts and increasing employment through new investments.
With the commissioning of our new high-tech production facilities, investments of which are still ongoing, we will make significant progress towards our 2025 goals, further strengthening our leadership in the Turkish pharmaceutical industry and our position in international markets. The increase in production in our facilities in Kazakhstan and Algeria will continue to add to our strength.
As we take these bold steps, we are aware of the fact that the power of R&D and human resources is the key to becoming an effective player in our industry. Our company, which allocates an above-industry percentage of its resources to R&D, contributes significantly to creating qualified human resources within the industry. We consider our 5,500 employees, 650 of whom are in international markets, as volunteer ambassadors of our 2025 vision.
We also prioritize sustainability. At Abdi İbrahim, we care about public health and leaving a world worth living in for future generations. As we launch facility investments that will strengthen our country and our industry and that best reflect our leadership position, we never lose our focus on environmental and social responsibility issues. We took an important step by starting to power our production facilities in Esenyurt with renewable energy sources. We aim to have achieved carbon neutrality by 2030. Having taken a pivotal step regarding water sustainability, Abdi İbrahim became the first Turkish pharmaceutical company to sign the CEO Water Mandate, the United Nations Global Compact initiative. We are happy to contribute to water conservation policies implemented around the globe through our commitments.
In line with our 2025 vision, we will further accelerate our sustainability efforts in the coming period. With a view to achieving our sustainability goals, we are collaborating with the best Turkish companies and start-ups in this field throughout the entire value chain for EV and EV truck deployment in logistics, reducing packaging waste and developing innovative packaging that is nature friendly. Moreover, we have prioritized participating in platforms such as CDP and RE100 where our company can share its breakthroughs in sustainability and benefit from the experience and know-how of the members of such platforms, and obtaining the ‘B Corp Certificate’ as a medium-term goal.
With long-established experience garnered through its 112-year history, Abdi İbrahim will continue to take firm steps towards the future and contribute to Türkiye’s economy, with courage, passion and a great sense of responsibility at its core.
Kind regards,
Dr. Süha Taşpolatoğlu
CEO
